Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials
New AI capabilities will help scientists identify, optimize, and validate new molecules. Additional applications include manufacturing, medical imaging, and enterprise AI agents
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Subscribe To Our Newsletter & Stay Updated